Whitehawk Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Whitehawk Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK
Investors are testing whether Whitehawk Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Whitehawk Therapeutics, Inc. (WHWK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
The story matters when it changes Whitehawk Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest WHWK filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Whitehawk Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →